Novel Method of Fat Suppression in Steady State Free Precession (SSFP) Based Magnetic Resonance Imaging (MRI)
Available for licensing is a technique for improving magnetic resonance imaging (MRI) that employs steady state free precession (SSFP). One such technique, fast imaging with steady-state free precession (FISP), is a well established and is a fast MR imaging method commonly used to evaluate cardiovascular anatomy and function. FISP provides high signal to noise ratio (SNR) images with excellent contrast between blood and the myocardium. However, these images are often contaminated with high signal from fatty tissue resulting in image artifacts. Conventional methods of fat signal suppression in FISP are often inefficient and...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Research Materials Diagnostics Licensing Desired NHLBI Source Type: research
Contrast Agent Enhancement of Chemical Exchange Dependent Saturation Transfer (CEDST) MRI
Available for licensing is an MRI image improving system wherein at least one contrast agent is administered to a subject in amounts effective to perform chemical exchange dependent saturation transfer (CEDST) MRI analysis.
Examples of contrast agents suitable for administration as exogenous contrast agents include at least one functional group bearing a proton capable of chemical exchange. Examples of these functional groups include, without limitation, amides, amines, and carboxyl, hydroxyl, and sulfhydryl groups.
The contrast agent can be administered as a solid, as a dispersion or solution, such as an aqueous compos...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Research Materials Diagnostics Licensing Desired NHLBI Source Type: research
Haplotypes of Human Bitter Taste Receptor Genes
Bitter taste has evolved in mammals as a crucial, important warning signal against ingestion of poisonous or toxic compounds. However, many beneficial compounds are also bitter, and taste masking of bitter tasting pharmaceutical compounds is a billion dollar industry. The diversity of compounds that elicit bitter-taste sensations is very large and more than two dozen members of the T2R bitter taste receptor family have been identified. Individuals are now known to be genetically predisposed to respond or not to respond to the bitter taste of a number of substances. For example, large individual differences in the perceptio...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Therapeutics Research Materials Diagnostics Licensing Desired NIDCD Source Type: research
Peptides With Laminin Activity
Peptides with laminin activity, including YIGSR, are claimed. These peptides block angiogenesis, alter the formation of capillary structures by endothelial cells, prevent the formation of excess blood vessels in tissue and inhibit in vivo tumor cell colonization of tissues. These peptides can be used, among other things, to inhibit metastasis.Inventors:
Frank Robey (NIDCR)
George Martin (NIDCR)
Hynda Kleinman (NIDCR)
Jeannette Graf ()
Makoto Sasaki (NIDCR)
Yoshihiko Yamada (NIDCR)
Yukihide Iwamoto ()Commercial Advantages:cancer therapeuticresearch reagentCompetitiv...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Licensing Desired Pre-clinical (in vivo) NIDCR Source Type: research
Laminin A Peptides
This invention relates to peptides and derivatives thereof having laminin-like activity, as well as a pharmaceutical composition of the peptide. The peptides claimed include Serine-Isoleucine-Lysine-Valine-Alanine-Valine (SIKVAV). Methods for promoting increased adhesion and migration of epithelial cells is also disclosed. The peptides have wide usage in research, nerve regeneration and cancer treatment. For example, this invention may be useful as an adhesion and regeneration agent for nerve guides and as an adhesion agent for vascular prosthesis.Inventors:
Hynda Kleinman (NIDCR)Commercial Advantages:adhesion a...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Research Materials Licensing Desired NIDCR Oncology Source Type: research
Probe To Identify Enteroinvasive E. coli And Shigella Species
Standard means for detecting pathogenic organisms in food or clinical specimens rely on animals or large DNA fragments, such as the 17 kb EcoRI fragment of Boileau. These methods are expensive, time-consuming, difficult to use, and have not been able to distinguish between nonvirulent enteroinvasive E. coli and Shigella. This invention describes DNA probes for enteroinvasive E. coli and Shigella species, including the sequence of the 2.5 kb fragment (SmaII and Falkow's) on which the probe is based.
The probe is more reliable, more sensitive, and less expensive than methods now in use.Inventors:
James Jagow ()
...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Diagnostics Licensing Desired Infectious Disease Source Type: research
Anti-Vaccinia Monoclonal Antibody
The current technology describes a monoclonal antibody that reacts with a vaccinia virus protein abundantly expressed under an early viral promoter after infection of cells. The antibody is useful for quantitating vaccinia virus infected cells and for studying the function of the protein to which it binds, which is known to be a double stranded RNA binding protein involved in resistance of the virus to interferons. This antibody is available for licensing through a biological materials license agreement.Inventors:
Jonathan (Jon) Yewdell (NIAID) (Source: NIH OTT Licensing Opportunities)
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Research Materials Licensing Desired NIAID Infectious Disease Source Type: research
HIV-1 Infection Detection Assay for Seroconverted HIV-1 Vaccine Recipients
Available for licensing and commercial distribution is a serological test specifically designed to distinguish between antibodies generated in HIV vaccine recipients and those generated in a natural HIV infection. The method is useful in HIV vaccine development and clinical studies as it can readily detect early breakthrough infections in seroconverted vaccine recipients, thus providing the information required to determine vaccine efficacy. The test kit includes diagnostic peptide fragments derived from human immunodeficiency virus-1 (HIV-1). The peptide epitopes are primarily derived from the GAG-p6 and gp41 genes. These...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Diagnostics Licensing Desired FDA Infectious Disease Source Type: research
Transcytosis of Adeno-Associated Viruses
The invention relates to a method for delivering nucleic acids to a variety of cells including those of the gut, kidney, lung and central nervous system. The underlying cells of such organs are covered by a barrier of endothelial or epithelial cells which can limit the transfer of nucleic acids, or other potentially therapeutic agents, to the underlying target cells. To overcome this limitation, the method employs certain members of the parvovirus family to transcytose the barrier cells. During transcytosis, the virus passes through these barrier cells and can infect cells of the underlying layer. Therefore, this method co...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Licensing Desired & Collaboration Desired Collaboration Sought NIDCR Source Type: research
Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
This technology relates to multimeric bacterial protein toxins which can be used to specifically target cells. Specifically, this is a modified recombinant anthrax toxin protective antigen (PrAg) that has been modified in several ways. First, the PrAg can be activated both by a metalloproteinase (MMP) and by urokinase plasminogen activator (uPA). Second, the native PrAg lethal factor (LF) binding site has been modified so that only a modified PrAg comprising two different monomers can bind anthrax LF. When administered with an effector component, the recombinant anthrax toxins are toxic only to cells expressing both a MMP ...
Source: NIH OTT Licensing Opportunities - July 21, 2021 Category: Research Authors: ott8admin Tags: Therapeutics Collaboration Sought NIDCR NIAID Oncology Immunology Source Type: research
Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial Infection
Technology Bundle IDNCI-E-171-2020
Synergistic Use of Exo VII Inhibitors And Quinolone Antibiotics For Treating Bacterial InfectionApplicationsTherapeuticsLead InventorsShar-yin Huang (NCI)Yves Pommier (NCI)Co-InventorsBrianna Mitchell (NCI)Development StatusPre-clinical (in vivo)ICsNCITopoisomerase poisons, such as quinolone antibiotics, are widely used as anticancer drugs and antibiotics. Quinolone antibiotics act by trapping prokaryotic type IIA topoisomerases (DNA gyrase and TOPO IV), resulting in irreversible topoisomerase cleavage complexes. However, current U.S. Food and Drug Administration (FDA) guidance reserves ...
Source: NIH OTT Licensing Opportunities - July 16, 2021 Category: Research Authors: ott8admin Source Type: research
Human Synovial Sarcoma Cell Line A2243
Technology Bundle IDNCI-E-160-2005
Human Synovial Sarcoma Cell Line A2243ApplicationsResearch MaterialsCo-InventorsNelson Ellmore ()Stuart Aaronson ()Development StatusDiscovery (Lead Identification)Synovial sarcoma is a cancer affecting mesenchymal cells in connective tissues. This rare cancer is typically linked to genetic abnormalities or exposure to radiation. Metastatic growth throughout the body can occur primarily through blood circulation. More than 90% of synovial sarcomas show a characteristic t(X;18)(p11;q11) translocation involving the SYT and SSX genes. The resulting SYT-SSX abnormal fusion protein causes mis...
Source: NIH OTT Licensing Opportunities - July 16, 2021 Category: Research Authors: ott8admin Source Type: research
T-cell Phenotypes Associated with Clinical Response to Adoptive Immunotherapy
Technology Bundle IDNCI-E-167-2019
T-cell Phenotypes Associated with Clinical Response to Adoptive ImmunotherapyApplicationsTherapeuticsLead InventorsSteven Rosenberg (NCI)Co-InventorsFrank Lowery (NCI)Gregoire Altan-Bonnet (NCI)Paul Robbins (NCI)Sri Krishna (NCI)Development StatusBasic (Target Identification)ICsNCIAdoptive T-cell therapy (ACT) utilizes tumor-reactive T cells to induce disease remission. While ACT has been used effectively to treat metastatic melanoma and certain epithelial cancers, most patients do not respond to treatment. Although the mechanisms underlying this variable response to therapy are not full...
Source: NIH OTT Licensing Opportunities - July 16, 2021 Category: Research Authors: ott8admin Source Type: research
Immunogens for Use in a High Efficacy HIV Vaccine
Technology Bundle IDNCI-E-160-2018
Immunogens for Use in a High Efficacy HIV VaccineLead InventorsGenoveffa Franchini (NCI)Co-InventorsGiacomo Gorini (NCI)Isabela Castro (NCI)Massimiliano Bissa (NCI)Timothy Cardozo (New York University)Development StatusPre-clinical (in vivo)ICsNCIHuman immunodeficiency virus (HIV) infections remain a pandemic, most prevalent in Africa and the Americas. Anti-retroviral treatments have been effective in preventing spread of the virus and active outbreaks of acquired immune deficiency syndrome (AIDS). However, the development and deployment of an effective vaccine would provide long-lasting...
Source: NIH OTT Licensing Opportunities - July 16, 2021 Category: Research Authors: ott8admin Source Type: research
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Technology Bundle IDNCI-E-291-2012
Chimeric Antigen Receptors to CD22 for Treating Hematological CancersApplicationsTherapeuticsLead InventorsIra Pastan (NCI)Co-InventorsCrystal Mackall (NCI)Dimiter Dimitrov (NCI)Rimas Orentas (NCI)Development StatusClinicalICsNCIChimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a ...
Source: NIH OTT Licensing Opportunities - July 16, 2021 Category: Research Authors: ott8admin Source Type: research
